FDA imposes 3-month delay on Paladin's Impavido
This article was originally published in Scrip
Executive Summary
The US FDA has delayed by three months its decision on the new drug application (NDA) for Paladin Labs Impavido (miltefosine) as a treatment for cutaneous, mucosal and visceral leishmaniasis, a parasitic disease transmitted by the phlebotomine sand flies and is found in parts of the tropics, subtropics and southern Europe.